Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Clinical trial NCT04079712 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04079712
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Large Cell Neuroendocrine Carcinoma Metastatic Neuroendocrine Carcinoma Metastatic Neuroendocrine Neoplasm Metastatic Small Cell Neuroendocrine Carcinoma

Start date: 2020-08-06
Primary completion: 2025-01-10
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.